{"id":881428,"date":"2025-09-03T08:58:32","date_gmt":"2025-09-03T12:58:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/"},"modified":"2025-09-03T08:58:32","modified_gmt":"2025-09-03T12:58:32","slug":"cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/","title":{"rendered":"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Sept.  03, 2025  (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak<sup>\u00ae<\/sup>\u00a0platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8<sup>th<\/sup> AntiViral Group (AVG) Meeting and 3<sup>rd<\/sup> International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore.<\/p>\n<p>\n        <strong>Presentation details are summarized below: <\/strong>\n      <\/p>\n<p>\n        <strong>Late-Breaking Abstract Title:<\/strong> NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy Adults<br \/><strong>Presenter:<\/strong> Rick Bright, Ph.D. Bright Global Health, Cidara Therapeutics<br \/><strong>Session:<\/strong> AVG Session 3 <br \/><strong>Session Date and Time:<\/strong> Wednesday, September 17, 2025, 3:50 \u2013 4:05 p.m. SGT<\/p>\n<p>\n        <strong>Abstract Title:<\/strong> A Single Prophylactic dose of CD388 Provides Protection Against Highly Pathogenic Bovine-Origin Influenza A (H5N1) Virus in the Ferret Model<br \/><strong>Presenter:<\/strong> Andreev Konstantin, Ph.D. St. Jude Children\u2019s Research Hospital <br \/><strong>Session:<\/strong> Parallel Session 2 (Track 1) <br \/><strong>Session Date and Time:<\/strong> Friday, September 19, 2025, 10:30 a.m. \u2013 12:30 p.m. SGT<\/p>\n<p>\n        <strong>About Cidara Therapeutics<\/strong><br \/>\n        <br \/>Cidara Therapeutics is using its proprietary Cloudbreak<sup>\u00ae<\/sup>\u00a0platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara\u2019s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CA1oosKHgl2achEu83YNmh_XpHZvkMbp8itBI-FcUQ1azNzAusjQT2O5NE6Ned05nXekLmnpShtaATbyC5Css9MYz9A9qggR_H707chUkkqTipbg4o2LUT795pHAZGvSzvisZDg-ECr6CLTpNxDx3V-FpNFWtQG0JQeSuzRJNzghArzYj3Z-y6T1su5R4ruXGM5VQrOTN_R8zcBpycXI2kqa-PW-uN6BV0zLc1pWvJgli-89RvDuCsya64NZbUHeALFPof6zpUHLUQI50QaAYBO81-g3xsos7f2KmcW6ULk=\" rel=\"nofollow\" target=\"_blank\">announced<\/a> positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Cidara is headquartered in San Diego, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=We1FdtpYV_9DeiQqv6OsNWsJhRuQ_zAbSqyguBpG1Z-6xgOVjm9IXKdHnwGqfSynbL-8IceLcOZIaEVol-_fPRPA_w8TPeSZbWvfXlnuaaPnLbicQ2y7TfFRf8BHofRi93L-w15i8LVn_KosHiXOKAnkL9coTBO2JrnuxV4yhxlRkPDDBIxN02lL4K9uXjPZcjLufprIHYkiSUB5xCBK4z8XI3EDwNWBGjLGvT4UybrgDpPa08vR30UzqXDAWQVUsJLSe456SfHl1W5F67bNo40O1-9ovDAT_XBBiYY9PazRlbw8ZHlvcJ5zZowckMprvbiZBVZesXzze4l-2wGB2qjLEKmQNRng2-Ger0AFUta7rEEM0w-V_M0rYtGer3bFdTUrrPtubJG-kAvcQxZuvYpmm6n_rKwrNwGJd2UR_98EtpuuLuLsKaUsCh_HTszNAGf0nKDUpJIFsh1yI9slAh_laiDKwd0yqwvaal0fyfV-NZdZTbdRMptHq9xrz-x6Ree4fX94RaXS7ysS7LlbzQ==\" rel=\"nofollow\" target=\"_blank\">www.cidara.com<\/a>.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors<br \/>(212) 915-2578<br \/>britchie@lifesciadvisors.com<\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Michael Fitzhugh<br \/>LifeSci Communications<br \/>(628) 234-3889<br \/>mfitzhugh@lifescicomms.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmMzYWJkMTItODM2MS00MmI3LTg5NmEtNmQ3NDNkMjc1ZjVlLTUwMDExMDg1NS0yMDI1LTA5LTAzLWVu\/tiny\/Cidara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae\u00a0platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore. Presentation details are summarized below: Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy AdultsPresenter: Rick Bright, Ph.D. Bright Global Health, Cidara TherapeuticsSession: AVG Session 3 Session Date and Time: Wednesday, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881428","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae\u00a0platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore. Presentation details are summarized below: Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy AdultsPresenter: Rick Bright, Ph.D. Bright Global Health, Cidara TherapeuticsSession: AVG Session 3 Session Date and Time: Wednesday, &hellip; Continue reading &quot;Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T12:58:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting\",\"datePublished\":\"2025-09-03T12:58:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/\"},\"wordCount\":311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/\",\"name\":\"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==\",\"datePublished\":\"2025-09-03T12:58:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting - Market Newsdesk","og_description":"SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae\u00a0platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore. Presentation details are summarized below: Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy AdultsPresenter: Rick Bright, Ph.D. Bright Global Health, Cidara TherapeuticsSession: AVG Session 3 Session Date and Time: Wednesday, &hellip; Continue reading \"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T12:58:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting","datePublished":"2025-09-03T12:58:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/"},"wordCount":311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/","name":"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==","datePublished":"2025-09-03T12:58:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjI0OSM3MTI3MjgwIzUwMDExMDg1NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-clinical-phase-2b-data-and-preclinical-h5n1-data-on-cd388-at-isrvs-8th-avg-and-3rd-imrp-2025-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV\u2019s 8th AVG and 3rd IMRP 2025 Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881428"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}